Valuation
26% of the score, 30% here after data gaps
33median 53
Alvotech is valued at 32.7x its operating profit, including debt: a very rich multiple.
60x
50x
35x
25x
18x
12x
8x
32.7x
Full points at 8x or less, none from 60xfull points
ALVOAlvotech
$4.59-48% 1Y
$4.59
$3.0052 weeks$8.72
RyuScore
Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
RyuScore 17 out of 100, Weak
Today's price. Only valuation depends on it.
Weak. Alvotech scores higher than 18% of the 2,231 companies Ryufin scores.
Held back by return on capital and valuation, with nothing carrying it far.
Healthcare median 19 · all companies 55
Return on capital
18% of the score, 20% here after data gaps
0median 24
Over 4 years the business earned -19% a year after tax on the capital it uses.
2%
8%
15%
25%
-19%
None at 2% or less, full points from 25%full points
4 years agolatest 4.9%
Return on new capital
16% of the score, 18% here after data gaps
0median 33
No operating profit over the period, so nothing was earned to reinvest.
Capital allocation
14% of the score, 16% here after data gaps
40median 63
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Share countUp 13.8% a year over 3 years: new shares
05%
-3%
14%
0 pointsfull points
Assets against salesAssets grew 26% a year, sales 100%
10012%
-2%
-74%
0 pointsfull points
Cycle position
Taken out: its 12% is shared by the others
n/ano data
Margins have been too thin to measure a cycle against.
Balance sheet
8% of the score, 9% here after data gaps
0median 50
What the debt weighs against the profit that has to carry it.
Net debt to EBITDA9.7x a year of EBITDA
04.5x
0.5x
9.7x
0 pointsfull points
Interest coverOperating profit covers interest 1x
01.5x
12x
0.5x
0 pointsfull points
Earnings quality
6% of the score, 7% here after data gaps
17median 90
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
AccrualsProfit ran ahead of cash by 5.8% of assets
178%
0%
-8%
5.8%
0 pointsfull points
How the RyuScore works
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. For ALVO, cycle position could not be measured from the filings, so it is taken out and the remaining weights scale up.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2025-12-31, latest annual report FY2025.
Drug Manufacturers, Specialty & Generic
Ranks #27 of 39 by RyuScore